Compare Gilead Sciences, Inc. (GILD) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Kinder Morgan Inc — how do they compare? Gilead Sciences, Inc. trades at $146.25 (market cap $182.40B), while Kinder Morgan Inc trades at $32.23 (market cap $71.81B). The key difference: Gilead Sciences, Inc. is far larger — about 2.5× Kinder Morgan Inc's market cap, and Kinder Morgan Inc pays the higher dividend (3.66%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Kinder Morgan Inc for 150 Days on average.
| GILD | KMI | |
|---|---|---|
Market Cap | $182.40B | $71.81B |
Volume | 4,469,821 | 16,921,908 |
Sector | Health | Energy |
52-Week High | $155.80 | $34.31 |
52-Week Low | $116.74 | $25.84 |
Typical Hold Time | 111 Days | 150 Days |
Enterprise Value | $205.46B | $103.86B |
Dividend Yield | 2.23% | 3.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Kinder Morgan (KMI) trades at $31.82, down 1.06% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with revenue growth from $15.1B in 2024 to $16.9B in 2025 and net income margins expanding to 19.31%. Recent earnings beats in Q4 2025 through Q2 2026 highlight operational strength, while a $6B-$7B growth pipeline supports future expansion in natural gas infrastructure.
KMI presents a compelling investment case with analyst consensus target of $37.20 offering 17% upside potential. The stock's 4% dividend yield and consistent cash flow generation provide income stability, though exposure to energy market volatility and high debt levels ($29.66B long-term debt) remain key risks. Wall Street sentiment is balanced with 47% buy ratings versus 50% hold recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
